Evidence map›Paper›PMID 34454615›Full record

ArticleActa neuropathologica communications2021

Disease-, region- and cell type specific diversity of α-synuclein carboxy terminal truncations in synucleinopathies.

Ethan W Hass, Zachary A Sorrentino, Yuxing Xia, Grace M Lloyd, John Q Trojanowski, Stefan Prokop, Benoit I Giasson

Open access · goldAbstract read
In one paragraph

Article in Acta neuropathologica communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
3.0field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Is Multiple System Atrophy a Prion-like Disorder?International journal of molecular sciences · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Ethan W Hass *Department of Neuroscience, College of Medicine, University of Florida, BMS J483/CTRND, 1275 Center Drive, Gainesville, FL, 32610, USA.
Zachary A Sorrentino *Department of Neuroscience, College of Medicine, University of Florida, BMS J483/CTRND, 1275 Center Drive, Gainesville, FL, 32610, USA.
Yuxing XiaDepartment of Neuroscience, College of Medicine, University of Florida, BMS J483/CTRND, 1275 Center Drive, Gainesville, FL, 32610, USA.
Grace M LloydDepartment of Neuroscience, College of Medicine, University of Florida, BMS J483/CTRND, 1275 Center Drive, Gainesville, FL, 32610, USA.
John Q TrojanowskiDepartment of Pathology and Laboratory Medicine, AD Center Core (ADCC), Center for Neurodegenerative Disease Research, PENN) School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA.
Stefan ProkopCenter for Translational Research in Neurodegenerative Disease, College of Medicine, University of Florida, Gainesville, FL, 32610, USA.
Benoit I GiassonDepartment of Neuroscience, College of Medicine, University of Florida, BMS J483/CTRND, 1275 Center Drive, Gainesville, FL, 32610, USA. bgiasson@ufl.edu.ORCID 0000-0003-2992-4234
University of Florida · USUniversity of Pennsylvania · US

Funding

Medicinal Chemistry CoreU19NS110456 · NINDS · UNIVERSITY OF PENNSYLVANIA · PI ROBERT H MACH · 2019 to 2026
$44.1M
Social Determinants of Health, Race/Ethnicity, and White Matter HyperintensitiesP30AG066506 · NIA · UNIVERSITY OF FLORIDA · PI David E Vaillancourt · 2020 to 2026
$25.6M
Project IV "Tackling Heterogeneity of Cognitive Trajectory in LBD"U19AG062418 · NIA · UNIVERSITY OF PENNSYLVANIA · PI TROJANOWSKI, JOHN Q. · 2019 to 2023
$18.1M
University of Florida - Mt. Sinai Medical Center AD Research CenterP50AG047266 · NIA · UNIVERSITY OF FLORIDA · PI FEBO, MARCELO · 2015 to 2019
$7.3M
Prion and non-prion induction mechanisms of alpha-synuclein pathologyR01NS100876 · NINDS · UNIVERSITY OF FLORIDA · PI BORCHELT, DAVID R, GIASSON, BENOIT I · 2018 to 2022
$1.9M
Mechanisms of Aggregated Alpha-Synuclein Induction and ProgressionR01NS089622 · NINDS · UNIVERSITY OF FLORIDA · PI GIASSON, BENOIT I · 2014 to 2018
$1.6M
Towards Understanding the Initiating Role of Truncated Alpha-Synuclein in NeurodegenerationF30AG063446 · NIA · UNIVERSITY OF FLORIDA · PI SORRENTINO, ZACHARY A · 2019 to 2022
$122k
Investigating Mechanisms of Neurodegeneration in Transgenic Mouse Models of TauopathiesF30AG067673 · NIA · UNIVERSITY OF FLORIDA · PI XIA, YUXING · 2021 to 2023
$110k
NIA NIH HHS F30 AG063446NIA NIH HHS F30AG063446NIA NIH HHS F30 AG067673NIA NIH HHS F30AG067673NIA NIH HHS P30 AG066506NIA NIH HHS P30AG066506NIA NIH HHS P50 AG047266NIA NIH HHS P50AG047266NIA NIH HHS U19 AG062418NIA NIH HHS U19AG062418NINDS NIH HHS L30 NS089022NINDS NIH HHS R01NS089022NINDS NIH HHS R01 NS089622NINDS NIH HHS R01 NS100876NINDS NIH HHS R01NS100876NINDS NIH HHS U19 NS110456NINDS NIH HHS U19NS110456
6 · The paper itself

Abstract

Synucleinopathies, including Parkinson's disease (PD), Lewy body dementia (LBD), Alzheimer's disease with amygdala restricted Lewy bodies (AD/ALB), and multiple system atrophy (MSA) comprise a spectrum of neurodegenerative disorders characterized by the presence of distinct pathological α-synuclein (αSyn) inclusions. Experimental and pathological studies support the notion that αSyn aggregates contribute to cellular demise and dysfunction with disease progression associated with a prion-like spread of αSyn aggregates via conformational templating. The initiating event(s) and factors that contribute to diverse forms of synucleinopathies remain poorly understood. A major post-translational modification of αSyn associated with pathological inclusions is a diverse array of specific truncations within the carboxy terminal region. While these modifications have been shown experimentally to induce and promote αSyn aggregation, little is known about their disease-, region- and cell type specific distribution. To this end, we generated a series of monoclonal antibodies specific to neo-epitopes in αSyn truncated after residues 103, 115, 119, 122, 125, and 129. Immunocytochemical investigations using these new tools revealed striking differences in the αSyn truncation pattern between different synucleinopathies, brain regions and specific cellular populations. In LBD, neuronal inclusions in the substantia nigra and amygdala were positive for αSyn cleaved after residues 103, 119, 122, and 125, but not 115. In contrast, in the same patients' brain αSyn cleaved at residue 115, as well as 103, 119 and 122 were abundant in the dorsal motor nucleus of the vagus. In patients with AD/ALB, these modifications were only weakly or not detected in amygdala αSyn inclusions. αSyn truncated at residues 103, 115, 119, and 125 was readily present in MSA glial cytoplasmic inclusions, but 122 cleaved αSyn was only weakly or not present. Conversely, MSA neuronal pathology in the pontine nuclei was strongly reactive to the αSyn x-122 neo-epitope but did not display any reactivity for αSyn 103 cleavage. These studies demonstrate significant disease-, region- and cell type specific differences in carboxy terminal αSyn processing associated with pathological inclusions that likely contributes to their distinct strain-like prion properties and promotes the diversity displayed in the degrees of these insidious diseases.

Indexed as

AgedAged, 80 and overalpha-SynucleinAlzheimer DiseaseAmygdalaAntibodies, MonoclonalEpitopesFemaleHumansLewy Body DiseaseMaleMiddle AgedMultiple System AtrophySynucleinopathiesTemporal Lobealpha-SynucleinAntibodies, MonoclonalEpitopesSNCA protein, humanCarboxyInclusionsLewy body dementiaMultiple system atrophyTruncationα-synuclein

Identifiers

PMID34454615
PMCPMC8403399
OpenAlexW3196548473

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.